Brookline Capital Management Estimates VRCA Q1 Earnings

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Equities researchers at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for shares of Verrica Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 11th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings per share of ($0.10) for the quarter. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share. Brookline Capital Management also issued estimates for Verrica Pharmaceuticals’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.34) EPS.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Verrica Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $9.50.

Verrica Pharmaceuticals Price Performance

VRCA opened at $0.60 on Thursday. Verrica Pharmaceuticals has a fifty-two week low of $0.54 and a fifty-two week high of $11.41. The business has a 50-day moving average of $0.68 and a 200-day moving average of $1.11. The company has a market capitalization of $27.32 million, a PE ratio of -0.33 and a beta of 1.44.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.30 million.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VRCA. Caligan Partners LP bought a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $5,201,000. Boothbay Fund Management LLC bought a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $1,811,000. Sovran Advisors LLC bought a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $267,000. Heights Capital Management Inc. bought a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $246,000. Finally, Rhumbline Advisers raised its stake in shares of Verrica Pharmaceuticals by 975.2% in the 4th quarter. Rhumbline Advisers now owns 266,093 shares of the company’s stock valued at $186,000 after acquiring an additional 241,344 shares in the last quarter. 42.45% of the stock is owned by institutional investors.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.